Educational Needs and Strategies of Pediatric Oncology Nurses in Low- and Middle-Income Countries

2014 ◽  
Vol 37 (4) ◽  
pp. E36-E47 ◽  
Author(s):  
Julia M. Challinor ◽  
Rachel Hollis ◽  
Carola Freidank ◽  
Cathérine Verhoeven
2020 ◽  
pp. 104345422091970
Author(s):  
Sara W. Day ◽  
Courtney E. Sullivan ◽  
Lisa Morrissey ◽  
Linda Abramovitz ◽  
Lorena Segovia ◽  
...  

The Nursing Working Group of the International Society of Pediatric Oncology developed baseline standards for pediatric oncology nursing care in low- and middle-income countries. The standards represent the foundational support required to provide quality nursing care and address barriers such as inadequate staffing, lack of support, limited access to education, and unsafe nursing environments. The purpose of the current study was to develop and validate an instrument to accurately measure the standards. Content validity was assessed by a panel of expert pediatric oncology nurses from all geographical regions of the World Health Organization. The experts were informed about the study’s purpose and provided the publications used to develop the instrument. The experts rated how well each criterion measured the corresponding standard by using a 4-point scale. A content validity index (CVI) was computed by using the percentage of total standards given a score of 3 or 4 by the experts. A CVI of .98 was obtained from the panel’s evaluation. A CVI of more than .80 is recommended for a newly developed instrument. On the basis of the panel’s recommendations, minor modifications were made to the instrument. We developed and validated the content of an instrument to accurately measure baseline standards for pediatric oncology nursing care. This instrument will aid future research on the effect of nursing standards on clinical outcomes, including mortality and abandonment of treatment, with the potential to influence health policy decisions and improve nursing support in low- and middle-income countries.


2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 237s-237s
Author(s):  
A. Gagnepain-Lacheteau ◽  
S. Vougier

Background and context: 20% of the children with cancer live in the high-income countries, where the survival rate is 80%, while 80% live in low- and middle-income countries, where the survival rate is <40%, and even lower in the poorest countries. Aim: In 2006 Sanofi Espoir Foundation launched the My Child Matters program, to give all the children with cancer, wherever they live, the same chance to have access to diagnosis and care. Strategy/Tactics: This program is based on public–private partnerships in the field of pediatric oncology in low- and middle-income countries. Program/Policy process: The program works with calls for projects, with 3-year-cycle grants founded by Sanofi Espoir Foundation. The first call for projects was launched in December 2005 in 10 countries, leading to 14 projects supported by the foundation. The last call for project was launched in 2015, the next one is expected at the end of 2018. The projects are various, according to the local needs, strengths and opportunities, and can focus on early diagnosis improvement, psychosocial support, treatment abandonment reduction, capacity building, cancer registries, development of palliative care and pain management or a holistic approach. They are selected by an international expert committee. The engineering involves the medical direction of Sanofi Espoir, a scientific overview in partnership with St. Jude Children’s Research Hospital, a mentoring program with the commitment of various international experts and some training sessions for the team. Strong partnerships are established with UICC, SIOP, St. Jude Children’s Research Hospital, Alliance Mondiale Contre le Cancer (French branch of INCTR), Groupe Franco Africain d'Oncologie Pédiatrique and some local associations and foundations. Outcomes: 58 projects implemented in 42 countries in Asia, Africa and Latin America. 18 on-going projects; 75,000 children cared for; 20,000 healthcare professionals trained; ∼100 scientific articles related to the My Child Matters have been published. An ancillary call for projects, dedicated to the nurses in pediatric oncology, have been launched as well in 2015. What was learned: At the local level, the team leadership, the efficacy of the mentor–mentee duo, the commitment of the local government, the partnerships with local associations are decisive in succeeding and reaching a sustainable model. At the international level, reinforcing partnerships with NGO and other foundations increases the opportunities of collaborations for improving the life of children with cancer and contributing to reach the SDG 3.


2019 ◽  
pp. 1-8
Author(s):  
Gabriel Revon-Rivière ◽  
Shripad Banavali ◽  
Laila Heississen ◽  
Wendy Gomez Garcia ◽  
Babak Abdolkarimi ◽  
...  

PURPOSE Low- and middle-income countries (LMICs) experience the burden of 80% of new childhood cancer cases worldwide, with cure rates as low as 10% in some countries. Metronomics combines frequent administrations of low-dose chemotherapy with drug repurposing, which consists of using already-approved drugs for new medical applications. With wide availability, limited costs, and little infrastructure needs, metronomics can be part of constraint-adapted regimens in these resource-limited settings—with the understanding that metronomics shall not be a substitute for standard treatments when available and doable. Our study aims to describe the experience, practices, opinions, and needs in metronomics of physicians working in LMICs. METHODS An online questionnaire was sent to more than 1,200 physicians in pediatric oncology networks in LMICs. Items included the type of center, physician’s demographics, experience in pediatric oncology, and experience with current knowledge of metronomics. Opinions and perspectives were explored using multiple-answer and open questions. RESULTS Of physicians, 17% responded. Of respondents, 54.9% declared that they had already used a metronomic regimen. The most frequently cited repositioned drugs were celecoxib (44%) followed by propranolol and valproic acid (17%). Respondents highlighted the advantages of outpatient use (20%) and expected low toxicity (24%). In considering the drawbacks of metronomics, 47% of responses highlighted the lack of scientific evidence or guidelines, 33% the availability or affordability of drugs, and 18% the problem of acceptance or compliance. Of physicians, 79% believed that use of metronomics will spread in LMICs in the near future and 98% of them were willing to participate in international metronomic protocols or registries. CONCLUSION Metronomics is already used in LMICs and is a potential answer to unmet needs in pediatric oncology. There is room for improvement in the availability of drugs and a necessity to develop collaborative protocols and research to generate level A evidence.


Sign in / Sign up

Export Citation Format

Share Document